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Abstract
Background: There is an unmet need for effective therapies for patients with advanced or
metastatic urothelial cancer who cannot tolerate cisplatin-based chemotherapy. Cisplatin-
ineligible patients experience a high frequency of adverse events from the most commonly
used standard of care treatment, carboplatin plus gemcitabine, or alternative treatment with
gemcitabine monotherapy. Pembrolizumab is a potent, highly selective humanised monoclo-
nal antibody that releases checkpoint inhibition of the immune response system, and provides
a new alternative for these patients.
Objective: To assess the cost-effectiveness of pembrolizumab for ﬁrst-line treatment of
urothelial carcinoma ineligible for cisplatin-based therapy in patients with strongly PD-L1–
positive tumours in Sweden.
Design, setting, and participants: Parametric survival curves were ﬁtted to overall
survival, progression-free survival, and time on treatment data from KEYNOTE-052 to extrap-
olate clinical outcomes. A simulated treatment comparison and a networkmeta-analysis were
conducted to estimate the comparative efﬁcacy of pembrolizumab versus carboplatin plus
gemcitabine and gemcitabine monotherapy. EQ-5D data from KEYNOTE-052 were used to
estimate utility, while resource use and cost inputs were estimated using Swedish regional
pricing lists and clinician opinion.
Outcome measurements and statistical analysis: The model reported costs, life years,
and quality-adjusted life years (QALYs), and results were tested using deterministic and
probabilistic sensitivity analysis.
Results and limitations: We estimated that pembrolizumab would improve survival by
2.11 and 2.16 years and increase QALYs by 1.71 and 1.75 compared to carboplatin plus
gemcitabine and gemcitabine monotherapy, respectively. Pembrolizumab was associated with
a cost increase ofs90 520 versus carboplatin plus gemcitabine ands95 055 versus gemcitabine,
with corresponding incremental cost-effectiveness ratios of s53 055/QALY and s54 415/QALY.
Conclusions: At awillingness-to-pay threshold ofs100 000/QALY, pembrolizumab is a cost-
effective treatment versus carboplatin plus gemcitabine and versus gemcitabine.
Patient summary: This is the ﬁrst analysis to show that pembrolizumab is a cost-effective
option for ﬁrst-line treatment of cisplatin-ineligible patients with locally advanced or meta-
static urothelial carcinoma in Sweden.
© 2018 Merck Sharp & Dohme Corp and The Authors. Published Elsevier B.V. on behalf of
European Association of Urology. This is an open access article under the CC BY-NC-ND license* Corresponding author. Center for Real World and Observational Studies, Merck & Co. Inc., 351 N.
Summneytown Pike, North Wales, PA 19454, USA. Tel.: +1 267 3051282.
zhong@merck.com (Y. Zhong).E-mail address: yichen.https://doi.org/10.1016/j.euo.2018.09.009
2588-9311/© 2018 Merck Sharp & Dohme Corp and The Authors. Published
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It is estimated that 24 500 people in Sweden are living with
urothelial cancer, a disease with an incidence of approxi-
mately 2700 cases per year and an average age of onset of
70 yr [1,2]. Several chemotherapies are available for first-
line treatment of patients with advanced and metastatic
urothelial cancer, both as monotherapies and as combina-
tion therapies. Although platinum-based treatments, espe-
cially those containing cisplatin, are preferred, these require
that patients are fit enough to tolerate such treatments
(meeting specific criteria including Eastern Cooperative
Oncology Group [ECOG] status 0–1). It has been estimated
that approximately half of all treated patients with locally
advanced andmetastatic urothelial cancer receive therapies
other than cisplatin-based regimens [3,4]. With a European
incidence rate of 151 297 [5] and assuming that 15% of
diagnoses are of stage IV (advanced disease requiring
systemic therapy) [6], at least 11 347 cisplatin-ineligible
patients across Europe would benefit from new therapies.
Although carboplatin plus gemcitabine is the preferred
treatment for cisplatin-ineligible patients [7], and gemci-
tabine monotherapy could be an alternative option for
patients who cannot tolerate combination chemotherapy,
currently available chemotherapies still have high frequen-
cies of adverse events (AEs) as they lack tumour tissue
specificity. There is therefore an unmet need for systemic
therapies that have both high efficacy and tolerability in
these patients; this is significant given the lack of major
advances in systemic therapy for urothelial cancer in almost
25 years [8].
Pembrolizumab (Keytruda) is a potent and highly
selective humanised monoclonal antibody designed to
cause dual ligand blockade of the PD-1 protein and release
the PD-1 pathway–mediated inhibition of the immune
response [9]. The efficacy of pembrolizumab in advanced
urothelial cancer was investigated in the KEYNOTE-052
trial. This was a single-arm phase 2 trial of pembrolizumab
in patients with locally advanced or metastatic urothelial
carcinoma who were not eligible for cisplatin-containing
chemotherapy and who had not been previously treated[(Fig._1)TD$FIG]
Fig. 1 – Model[10]. Trial outcomes were also assessed on the basis of
whether patients’ tumours were positive or strongly
positive for PD-L1 expression. Pembrolizumab has been
approved by the European Medicines Agency for the
treatment of locally advanced or metastatic urothelial
carcinoma in adults who are not eligible for cisplatin-
containing chemotherapy with strongly PD-L1–positive
tumours (express PD-L1 with a combined positive score
[CPS]10) on the basis of strong phase 2 data [11]. Approxi-
mately 30% of cisplatin-ineligible patients are expected to
have strongly PD-L1–positive tumours [12]. For patients in
countries with a Health Technology Assessment (HTA)
system, access to a new innovative treatment depends on a
reimbursement decision supported by cost-effectiveness
analyses.
This study estimated the cost-effectiveness of pembro-
lizumab versus current standard of care (SOC) for the
treatment of cisplatin-ineligible patients with advanced,
unresectable, or metastatic urothelial cancer and strongly
PD-L1–positive tumours from a Swedish healthcare per-
spective.
2. Patients and methods
2.1. Model structure
A partitioned-survival model was used to estimate health outcomes and
costs for pembrolizumab and each comparator in the target patient
population. The model structure included three mutually exclusive
health states (progression-free, progressive disease, and death), as
shown in Figure 1.
The proportion of patients in each health state at given time points
was calculated using the partitioned-survival approach. Patients remain
in the starting progression-free health state until disease progression or
death, while the progressive disease health state encompasses patients
alive after ﬁrst progression and before death, which iswhere they remain
until the end of the model.
Outputs from this model include costs, life years, and quality-
adjusted life years (QALYs), which inform the incremental cost-
effectiveness ratio (ICER). Costs and health outcomes were discounted
at a rate of 3% per year, and a time horizon of 15 yr (lifetime) with a
weekly model cycle was used for the base case [13].structure.
[(Fig._2)TD$FIG]
Fig. 2 – Kaplan-Meier (KM) and fitted survival curves. SOC = standard of
care (gemcitabine plus carboplatin).
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time on treatment for pembrolizumab
Parametric survival models were ﬁtted to the KEYNOTE-052 Kaplan-
Meier data for patients with strongly PD-L1–positive tumours to model
overall survival (OS), progression-free survival (PFS), and time on
treatment (ToT). Piecewise extrapolation was used in the PFS and OS
survival models by directly applying Kaplan-Meier data before a cutoff
point (chosen on the basis of observed structural changes), followed by
parametric models ﬁtted to the remaining data. In the base case, 9 and
32 wk were used for PFS and OS cutoff points, respectively. This captures
the different shapes and trajectories of individual curves over time,
rather than attempting to ﬁt a single curve to a complex-shaped Kaplan-
Meier graph. Survival curve ﬁtting was carried out in line with National
Institute for Health and Care Excellence (NICE) guidelines [14]. The base-
case choice curves ﬁtted for each outcome are presented in Figure 2. The
Akaike information criterion and the Bayesian information criterion,
combined with visual inspection and the clinical plausibility of
extrapolated curves (as advised by a bladder cancer clinician), were
used to select the best-ﬁt parametric distributions for the base case.
Exponential, log-normal, and Gompertz were selected as the base-case
curves for PFS, OS, and ToT, respectively, with alternative Kaplan-Meier
cutoff points and extrapolations tested in scenario analyses.
2.3. Modelling OS and PFS for comparators
According to national guidelines and clinical opinion [1], carboplatin
plus gemcitabine is provided as current ﬁrst-line SOC for patients
ineligible for cisplatin-containing chemotherapy in Sweden. Although
not SOC, gemcitabine monotherapy was identiﬁed as another potential
treatment option as part of a systematic literature review [15]. Therefore,
both treatments were used as comparators in the model.
As KEYNOTE-052 was a single-arm study and none of the comparator
trials included a pembrolizumab arm, it was not possible to construct a
connected or anchored network meta-analysis (NMA) to estimate a
comparative treatment effect for pembrolizumab versus the other
treatments. Therefore, a simulated treatment comparison (STC) was
performed using patient-level data from KEYNOTE-052 to ﬁt prediction
models for pembrolizumab OS and PFS considering a range of relevant
patient characteristics of prognostic value, including the proportion of
patients with liver and visceral metastases, performance score (ECOG
status), andrenal function. Theﬁttedpredictionmodelwas thenapplied to
estimate the OS and PFS for a simulated pembrolizumab arm for patients
with strongly PD-L1–positive tumours in relevant comparator trials
identiﬁed via systemic review, using reported aggregate patient char-
acteristics [7,15–18]. NMAwas thenperformed using data fromKEYNOTE-
052andthecomparator trials (includingtheobservedcomparatorarmand
a simulated pembrolizumab arm) to estimate time-constant OS and PFS
hazard ratios for the comparator treatments versus pembrolizumab.
For the model base case, the time-constant hazard ratio for OS was
2.78 for carboplatin plus gemcitabine and 2.94 for gemcitabine versus
pembrolizumab. For PFS the hazard ratio was 1.64 for both comparators
versus pembrolizumab. Pembrolizumab and comparator survival extra-
polations (for gemcitabine plus carboplatin only) are presented in
Figure 2.
General populationmortality was calculated from Swedish life tables
[19]. The maximum cycle hazard between general population mortality
and extrapolated parametric survival curves was applied for each arm
during each model cycle.
2.4. Adverse events
For all treatments, all-cause grade 3 AEs that occurred in more than 5%
of patients from corresponding clinical trials were included to calculateboth costs and utilities (for the SOC comparator arm, AE frequencieswere
averaged for all four trials included, weighted by the number of patients
per trial) [7,15–18].
2.5. Health-related quality of life
For each health state, a speciﬁc quality-of-life adjustment weight (a
utility, where 1 is full health and 0 is death) was assigned to calculate the
cumulative QALYs over the time horizon modelled. The base-case
utilities were calculated using EQ-5D data for patients with strongly PD-
L1–positive tumours in KEYNOTE-052 and using the Swedish scoring
algorithm [20]. The average utility was 0.842 for progression-free
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Utilities based on time-to-death categories were used in another
scenario analysis [21]. The same utility values were applied in both
the pembrolizumab and comparator arms. An average disutility of
0.041 for any all-cause grade 3 AE was estimated using differences
between the utility for progression-free patients with andwithout grade
3 AEs. This was then multiplied by the average duration of AEs from
KEYNOTE-052 (0.07 yr) and the probability of experiencing any grade3
AE. These QALY decrements were applied once at the start of the model.
2.6. Costs and resource utilisation
Drug costs for pembrolizumabwere based on ToT curves combined with
the KEYNOTE-052 ﬁxed dosing schedule of 200 mg intravenously every
3 wk (Q3W). A maximum treatment duration of 35 treatment cycles
(104 wk) was applied for the pembrolizumab arm, while ToT was
assumed to be equal to PFS for the comparators. The dosing schedule for
gemcitabine monotherapy was 1000 mg/m2 intravenously per week for
3 wk, followed by a 1-wk rest. For carboplatin plus gemcitabine
combination therapy the schedule was 1000 mg/m2 intravenous
gemcitabine on days 1 and 8, and 512 mg intravenous carboplatin on
day 1, every 3 wk [22]. All treatments were assigned an administration
cost of s263.90 in accordance with the Swedish regional price list
[23]. Subsequent treatment costs were not included in the base case.
To identify one patient with a strongly PD-L1–positive tumour,
approximately three patients need to be tested for tumour PD-L1 status
(since 30% of patients have strongly PD-L1–positive tumours) [12]. A
single PD-L1 testwas costed ats102.59 (list price ofs5129.40 for a PD-L1
testing kit containing 50 tests) [24].
All-cause grade 3 AEs that occurred in more than 5% of patients
were assigned management costs from the regional price list [23]. One-
off average AE costs were totalled for each treatment arm and applied at
the start of the model on the basis of overall AE probabilities and
management costs.
Resource utilisation estimates were sourced from a survey of four
clinicians, with unit costs from the regional price list [23]. This yielded
weekly monitoring costs of s69.54 in the progression-free health state
ands94.07 in the disease progression state. The cost of terminal carewas
applied upon death and was based on the 2014 ipilimumab Tandvårds-
och läkemedelsförmånsverket submission (s7226.30) [25].
2.7. Sensitivity analysis
One-way sensitivity analysis was performed by varying each input to its
lower and upper bounds and recording the impact on themodel result. In
addition, a probabilistic sensitivity analysis was run, with all inputs
assuming a random value across their individual distributions. Scenario
analysis tested model sensitivity to speciﬁc parameters, such as survival
curve extrapolations, treatment stopping rules, and EQ-5D tariffs. Key
model inputs and their distributions are summarised in Supplementary
Table 1. The willingness-to-pay threshold was based on the high cost perTable 1 – Incremental cost-effectiveness results (pairwise comparisons
Cost (s) LYs QALYs
Incremental costs (s) In
Pembrolizumab 119 366.12 2.93 2.38
Carbo + Gem 28 845.92 0.82 0.67 90 520.20
Gemcitabine 24 311.12 0.77 0.63 95 055.00
Carbo + Gem = carboplatin plus gemcitabine (standard of care); ICER, increme
incremental LYs or incremental QALYs); LY = life year (can be interpreted as mean
interpreted as mean QALY over the time horizon modelled).QALY value published by the Sweden National Board (500 000–
1 000 000 kronor/s50 000–100 000) [26], and validated using the cost
per QALY for previously accepted treatments in Sweden [27]..
3. Results
The base-case model results reveal that pembrolizumab
provides more life years and QALYs than both carboplatin
plus gemcitabine and gemcitabinemonotherapy, improving
survival by 2.11 and 2.16 yr and QALYs by 1.71 and 1.75,
respectively (the life years and QALYs are mean estimates
over the time horizon modelled). Pembrolizumab is
associated with increases in costs of s90 520 versus
carboplatin plus gemcitabine and s95 055 versus gemci-
tabine; the ICER for pembrolizumab iss53 055/QALYversus
carboplatin plus gemcitabine and s54 415/QALY versus
gemcitabine monotherapy (Table 1). The modelled esti-
mates for patients in the progression-free, progression, and
death states for the different treatment arms over themodel
time horizon are presented in the Supplementary Table 1.
A one-way sensitivity analysis showed that parameters
informing pembrolizumab ToT, OS, and dose intensity had
the greatest effect on the model results (Fig. 3 and
Supplementary Table 1 [owing to the similarity in results,
only the results for carboplatin plus gemcitabine are shown
here]). Probabilistic sensitivity analysis based on 1000 itera-
tions suggested that pembrolizumab was more cost-
effective than carboplatinplus gemcitabinewith probability
of 87% at a willingness-to-pay threshold of s100 000
(Fig. 4). The ICERwas robust to changes in scenario analysis,
such as methods for estimating utility (including the use of
UK EQ-5D tariffs to calculate utility values) and subsequent
treatment assumptions, but scenarios regarding maximum
treatment duration and OS extrapolations were highly
influential (Supplementary Table 2).
4. Discussion
The model results indicate that pembrolizumab improves
life expectancy compared to its comparators. Interpretation
of cost-effectiveness always depends on the willingness-to-
pay threshold specific to the model perspective and setting,
but pembrolizumab provides QALY gains at ICERs that are
lower than those for treatments previously approved for
reimbursement in Sweden, and within the high cost-per-
QALY threshold defined by the National Board of Health and
Welfare (s50 000–100 000) [26,27].) for the base case
Pembrolizumab versus comparator
cremental LYs Incremental QALYs ICER (s/QALY) ICER (s/LY)
2.11 1.71 53 055.42 42 967.32
2.16 1.75 54 414.78 44 025.65
ntal cost-effectiveness ratio (calculated as incremental costs divided by
lifetime over the time horizon modelled); QALY = quality-adjusted LY (can be
[(Fig._3)TD$FIG]
Fig. 3 – One-way sensitivity analysis for pembrolizumab versus standard of care (SOC). AE = adverse event; ICER = incremental cost-effectiveness ratio;
KN052 = KEYNOTE-052; Lnormal = log-normal; OS = overall survival; PFS = progression-free survival.
[(Fig._4)TD$FIG]
Fig. 4 – Cost-effectiveness acceptability curve. SOC = standard of care (carboplatin plus gemcitabine).
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with extrapolation and comparative efficacy methodology
validated using health economic experts, and key clinical
inputs and assumptions sourced from Swedish clinical
experts. Median OS predicted from the model closely
matches latest median OS observed from KEYNOTE-052
(PD-L1 CPS 10 subgroup: 18.4 vs 18.5 mo) [12]. The
calculations presented here were based on the health care
system and drug pricing in Sweden, but estimates of life
years and QALYs gained are likely to be comparable across
other European countries. Should resource utilisation,
treatment costs, and AE management costs prove to be
similar between countries, overall cost-effectiveness results
are also likely to be generalisable.
One limitation of the model is the lack of direct
comparison of pembrolizumab with the comparators in a
randomised controlled trial. As KEYNOTE-052 was a single-
arm study, pembrolizumab cannot be directly connected to
the evidence network (ie, only an “unanchored” network for
pembrolizumab and comparators can be constructed). Thecomparative efficacy for the comparators versus pembro-
lizumab was therefore based on an STC in which patient-
level data from KEYNOTE-052 were used to fit a prediction
model considering a range of patient characteristics. This
prediction model was then used to construct a simulated
pembrolizumab arm for each comparator trial based on the
aggregated patient characteristics reported in each com-
parator trial. STC is one of the methods recommended by
the recent NICE Decision Support Unit guidance on
performing population-adjusted indirect comparisons for
an “unanchored” network for which patient-level data exist
for the intervention trial but only aggregate data are
available from the comparator trial. However, there are
significant limitations related to the use of an STC or any
other currently available method that derives comparative
efficacy in an “unanchored” network [28]. In addition, we
made a simplifying assumption by using constant hazard
ratios in the base case; whether the proportional hazard
assumption truly holds over the modelled time horizon is
uncertain. Although OS projections and relative comparator
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to treatment waning after 5 yr in the scenario analysis.
Additional uncertainty is found in the assumed pembroli-
zumab treatment duration (ie, maximum of 2 yr), as per the
KEYNOTE-052 protocol, which may not be consistent with
real-life practice.
The phase 2 KEYNOTE-052 trial showed very promising
durable efficacy and high tolerability for pembrolizumab,
and provided a new treatment option in the first-line
setting for cisplatin-unfit patients [29]. Longer follow-up
from KEYNOTE-052 can provide more mature OS and ToT
data to improve model extrapolations [12], but this will still
be in the context of a single-arm phase 2 trial. A future
randomised controlled phase 3 trial, KEYNOTE-361
(NCT02853305), is likely to help inform and/or validate
modelled results by providing head-to-head data with a
relevant comparator [30].
5. Conclusions
The results show that pembrolizumab is a cost-effective
option for first-line treatment of locally advanced or
metastatic urothelial carcinoma in cisplatin-ineligible
patients with strongly PD-L1–positive tumours in Sweden
at a willingness-to-pay threshold of s100 000, with
potential survival and QALY benefit compared to che-
motherapies.
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